Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice

Vaccine

Volumn 29, Issue 46, 2011, Pages 8222-8229

  Camacho, A I ^a   De Souza, J ^a   Sanchez Gomez S ^a   Pardo Ros, M ^a   Irache, J M ^a   Gamazo, C ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adjuvant; Nanoparticles; Outer membrane vesicles; Shigella; Vaccine

Indexed keywords

COPOLYMER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; NANOPARTICLE; OUTER MEMBRANE VESICLE; POLYANHYDRIDE; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DYSENTERY, BACILLARY; EXOSOMES; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; MICE; MICE, INBRED BALB C; NANOPARTICLES; SHIGELLA FLEXNERI; SHIGELLA VACCINES; SURVIVAL ANALYSIS;

EID: 80053967497     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.121     Document Type: Article

References (51)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77(8):651-666.
2. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5(July (7)):540-553.
3. Kweon M.N. Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 2008, 21(June (3)):313-318.
4. Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 2009, 8(December (12)):1693-1704.
5. Tamayo I., Irache J.M., Mansilla C., Ochoa-Reparaz J., Lasarte J.J., Gamazo C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol 2010, 17(September (9)):1356-1362.
6. Ochoa J., Irache J.M., Tamayo I., Walz A., DelVecchio V.G., Gamazo C. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. Vaccine 2007, 25(May (22)):4410-4419.
7. Gomez S., Gamazo C., San R.B., Vauthier C., Ferrer M., Irachel J.M. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J Nanosci Nanotechnol 2006, 6(September (9-10)):3283-3289.
8. Salman H.H., Gamazo C., Campanero M.A., Irache J.M. Salmonella-like bioadhesive nanoparticles. J Control Release 2005, 106(August (1-2)):1-13.
9. Gomez S., Gamazo C., Roman B.S., Ferrer M., Sanz M.L., Irache J.M. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine 2007, 25(July (29)):5263-5271.
10. Kulp A., Kuehn M.J. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 2010, 64(October (13)):163-184.
11. Fernandez-Moreira E., Helbig J.H., Swanson M.S. Membrane vesicles shed by Legionella pneumophila inhibit fusion of phagosomes with lysosomes. Infect Immun 2006, 74(June (6)):3285-3295.
12. Kesty N.C., Mason K.M., Reedy M., Miller S.E., Kuehn M.J. Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells. EMBO J 2004, 23(November (23)):4538-4549.
13. Kadurugamuwa J.L., Beveridge T.J. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol 1995, 177(July (14)):3998-4008.
14. Wai S.N., Lindmark B., Söderblom T., Takade A., Westermark M., Oscarsson J., et al. Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin. Cell 2003, 115(October (1)):25-35.
15. Mallett C.P., Hale T.L., Kaminski R.W., Larsen T., Orr N., Cohen D., et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 1995, 63(June (6)):2382-2386.
16. Horstman A.L., Kuehn M.J. Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. J Biol Chem 2000, 275(April (17)):12489-12496.
17. Bahnemann H.G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 1990, 8(August (4)):299-303.
18. Gamazo C., Winter A.J., Moriyon I., Riezu-Boj J.I., Blasco J.M., Diaz R. Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect Immun 1989, 57(May (5)):1419-1426.
19. Marolda C.L., Lahiry P., Vines E., Saldias S., Valvano M.A. Micromethods for the characterization of lipid A-core and O-antigen lipopolysaccharide. Methods Mol Biol 2006, 347:237-252.
20. Lee C.H., Tsai C.M. Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 1999, 267(February (1)):161-168.
21. Horstman A.L., Bauman S.J., Kuehn M.J. Lipopolysaccharide 3-deoxy-D-manno-octulosonic acid (Kdo) core determines bacterial association of secreted toxins. J Biol Chem 2004, 279(February (9)):8070-8075.
22. Bahrani F.K., Sansonetti P.J., Parsot C. Secretion of Ipa proteins by Shigella flexneri: inducer molecules and kinetics of activation. Infect Immun 1997, 65(October (10)):4005-4010.
23. Arbos P., Wirth M., Arangoa M.A., Gabor F., Irache J.M., Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release 2002, 83(October (3)):321-330.
24. Diaz R., Bosseray N. Study of the antigenic relations between Yersina enterocolitica serotype 9 and other Gram negative bacterial strains. Microbiol Esp 1974, 27(January (1)):1-14.
25. Mukhopadhaya A., Mahalanabis D., Chakrabarti M.K. Role of Shigella flexneri 2a 34kDa outer membrane protein in induction of protective immune response. Vaccine 2006, 24(August (33-34)):6028-6036.
26. Al-Hasani K., Navarro-Garcia F., Huerta J., Sakellaris H., Adler B. The immunogenic SigA enterotoxin of Shigella flexneri 2a binds to HEp-2 cells and induces fodrin redistribution in intoxicated epithelial cells. PLoS One 2009, 4(12):e8223.
27. Parsot C., Menard R., Gounon P., Sansonetti P.J. Enhanced secretion through the Shigella flexneri Mxi-Spa translocon leads to assembly of extracellular proteins into macromolecular structures. Mol Microbiol 1995, 16(April (2)):291-300.
28. Kadurugamuwa J.L., Beveridge T.J. Delivery of the non-membrane-permeative antibiotic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles. Antimicrob Agents Chemother 1998, 42(June (6)):1476-1483.
29. Levine M.M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010, 8:129.
30. Canh D.G., Lin F.Y., Thiem V.D., Trach D.D., Trong N.D., Mao N.D., et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004, 72(November (11)):6586-6588.
31. Jennison A.V., Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 2004, 28(February (1)):43-58.
32. Sansonetti P.J., Tran Van N.G., Egile C. Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Clin Infect Dis 1999, 28(March (3)):466-475.
33. Li A., Rong Z.C., Ekwall E., Forsum U., Lindberg A.A. Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients. Scand J Infect Dis 1993, 25(5):569-577.
34. Ellis T.N., Kuehn M.J. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 2010, 74(March (1)):81-94.
35. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 2007, 179(December (11)):7692-7701.
36. Aoki M., Kondo M., Nakatsuka Y., Kawai K., Oshima S. Stationary phase culture supernatant containing membrane vesicles induced immunity to rainbow trout Oncorhynchus mykiss fry syndrome. Vaccine 2007, 25(January (3)):561-569.
37. Zhang T., Hashizume T., Kurita-Ochiai T., Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem Biophys Res Commun 2009, 390(December (3)):937-941.
38. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(June (Suppl 2)):B3-B12.
39. Schroeder G.N., Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 2008, 21(January (1)):134-156.
40. Biswas A., Banerjee P., Mukherjee G., Biswas T. Porin of Shigella dysenteriae activates mouse peritoneal macrophage through Toll-like receptors 2 and 6 to induce polarized type I response. Mol Immunol 2007, 44(February (5)):812-820.
41. Phalipon A., Sansonetti P.J. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?. Immunol Cell Biol 2007, 85(February (2)):119-129.
42. Sanders H., Feavers I.M. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines 2011, 10(March (3)):323-334.
43. Rimoldi M., Chieppa M., Salucci V., Avogadri F., Sonzogni A., Sampietro G.M., et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005, 6(May (5)):507-514.
44. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(October (5)):488-496.
45. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82(October (5)):497-505.
46. Bungener L., Geeraedts F., Ter V.W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26(May (19)):2350-2359.
47. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999, 67(July (7)):3437-3443.
48. Oberhelman R.A., Kopecko D.J., Salazar-Lindo E., Gotuzzo E., Buysse J.M., Venkatesan M.M., et al. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect Immun 1991, 59(July (7)):2341-2350.
49. Bird L. T cells: TLRs deliver a direct hit to TH17 cells. Nat Rev Immunol 2010, 10(June (6)):384.
50. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470(February (7335)):543-547.
51. Sellge G., Magalhaes J.G., Konradt C., Fritz J.H., Salgado-Pabon W., Eberl G., et al. Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity. J Immunol 2010, 184(February (4)):2076-2085.